Results 71 to 80 of about 147,146 (257)

A Personalized, 3D Printed Polymeric Device for the Prevention of Post‐Myocardial Infarction Cardiac Remodeling

Advanced Healthcare Materials, EarlyView.
Myocardial infarction often leads to pathological remodelling and ventricular dilatation, key features of HFrEF. This study introduces a personalized, 3D‐printed cardiac restraint device (CARD) printed using rationally designed inks displaying the requested printability and mechanical properties.
Nicola Mansour, Daniel Cohn, Ishita Sarkar, Raja Alamore, Kareem Abd Rbo, Offer Amir, Dean Nachman   +6 more
wiley   +1 more source

Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Heart failure guidelines have recently introduced a narrow category with mildly reduced left ventricular ejection fraction (LVEF) (heart failure with mildly reduced ejection fraction; LVEF 41%–49%) between the previous categories of reduced ...
Malin Christersson, Stefan Gustafsson, Erik Lampa, Matilda Almstedt, Thomas Cars, Johan Bodegård, Gabriel Arefalk, Johan Sundström   +7 more
doaj   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift

South African Family Practice, 2016
Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care.
M. O.E. Irhuma, M. Vally
doaj   +1 more source

Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction

Clinical and Experimental Hypertension, 2020
Background: It is unclear that the difference in efficacy of tolvaptan (TLV) on the length of hospital stay for both heart failure (HF) preserved ejection fraction (EF) (HFpEF) and reduced EF (HFrEF) patients.
Shunsuke Kiuchi, Shinji Hisatake, Takayuki Kabuki, Takashi Oka, Shintaro Dobashi, Takahiro Fujii, Takanori Ikeda   +6 more
doaj   +1 more source

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

Advanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang, Wing Yan Chung, Serena M. Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M. Morrow, Ilka Lorenzen‐Schmidt, Fengxia Xiao, Augusto Zani, Dylan Burger, Hye Kyoung Sung, Erin E. Mulvihill, Gary Sweeney   +13 more
wiley   +1 more source

Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration

Advanced Healthcare Materials, EarlyView.
Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu, Yongjie Tang, Sidi Liu, Tao Xu, Qian Liu   +4 more
wiley   +1 more source

Role of interleukins in heart failure with reduced ejection fraction

Anatolian Journal of Cardiology, 2019
Heart failure (HF) is the leading cause of morbidity and mortality in developed countries, and it is the primary cause of mortality in the elderly worldwide.
Oliwia Anna Segiet, Adam Piecuch, Lukasz Mielanczyk, Marek Michalski, Ewa Nowalany-kozielska   +4 more
doaj   +1 more source

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

Advanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen, Neona M. Lowe, Sophia Kellogg, Kuan‐Wei Huang, Hannah O'Toole, Elizabeth J. Hale, Venktesh S. Shirure, Bhupinder S. Shergill, Steven C. George, Randy P. Carney   +9 more
wiley   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source